ERMA Systems Launches Q1 AI Pilot with Life Science Innovators, Welcomes Brandon Schlette to Advisory Board

MIAMI--(BUSINESS WIRE)--ERMA Systems™, the AI-powered compliance platform redefining how life-sciences companies manage medical, legal, and regulatory (MLR/PRC) review, announced today that multiple organizations will participate in its Q1 2026 pilot program—an 8–10-week evaluation designed to validate ERMA’s technology in real-world pharmaceutical workflows.

In a major step forward for its governance and industry leadership, ERMA Systems also announced that Brandon Schlette, Senior Commercial leader, will join ERMA’s Advisory Board. Schlette’s expertise in rare-disease commercialization and operational innovation will help guide ERMA’s growth strategy as the platform prepares for broader industry rollout.

“Brandon is one of the rare leaders who not only understands the operational realities of rare disease commercialization but also actively pushes for smarter, more modern technology to support it,” said Julia Gardner, Founder & CEO of ERMA Systems. “His ability to champion innovation has been instrumental in shaping how teams adopt new digital tools. Having someone with his forward-thinking mindset join our advisory board accelerates ERMA’s mission to bring truly next-generation compliance technology to the industry.”

Participating organizations in the Q1 pilot will pressure-test ERMA’s AI-driven platform, underscoring the industry’s growing desire for compliance technology that is modern, automated, and built to keep pace with accelerating FDA expectations.

ERMA’s platform integrates proprietary AI models capable of ingesting medical documents, data visualizations, scientific annotations, and FDA-cited references. The system’s flagship engine, ERMA Evaluate™, is continuously trained on evolving FDA promotional regulations, enabling teams to detect risk earlier and complete review cycles faster.

What the Q1 Pilot Will Evaluate

Over the 8–10-week program, participating companies will test:

• AI-powered risk detection aligned with the latest FDA promotional guidance
• Automated reference extraction and assignment, reducing manual review burden
• Modern workflow and routing capabilities purpose-built for MLR/PRC teams
• Real-time collaboration tools, including commenting and audit-ready documentation
• Actionable data insights to enable faster review cycles and greater compliance confidence

The pilot is a foundational step toward ERMA’s larger commercial rollout in 2026.

About ERMA Systems

ERMA Systems is building the next generation of life-sciences compliance technology. Designed to replace outdated legacy systems, ERMA leverages proprietary AI models, automated reference management, and intelligent FDA-trained risk detection to radically streamline MLR/PRC review workflows. ERMA helps emerging and mid-market teams get ahead of new regulatory expectations while reducing time, cost, and friction across the review process.